A program to develop new treatment strategies for pediatric cancer patients with limited options
Feasibility of Generating Novel Translational and Therapeutic Strategies Based on a Multicenter, Pediatric and AYA Evolutionary Tumor Board (pedsETB)
This study is testing a new program that brings together experts to find better treatment options for kids with cancer who have few choices left.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 35 (estimated) |
| Sex | All |
| Sponsor | H. Lee Moffitt Cancer Center and Research Institute Academic / other |
| Locations | 1 site (Tampa, Florida) |
| Trial ID | NCT06423950 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the effectiveness of the Pediatric Evolutionary Tumor Board (pedsETB), a multidisciplinary and multisite group, in creating additional therapeutic strategies for pediatric cancer patients who are considered likely incurable. The focus is on patients who have newly diagnosed cancer, relapsed, or are in remission but at high risk of recurrence, and who have not responded well to previous treatments. The study aims to gather clinical data and insights from various experts to improve outcomes for these patients.
Who should consider this trial
Good fit: Ideal candidates include pediatric and adolescent patients with cancer who are considered likely incurable based on standard care.
Not a fit: Patients who have curable cancer or those who do not meet the performance status criteria may not benefit from this study.
Why it matters
Potential benefit: If successful, this initiative could provide new therapeutic options for pediatric cancer patients who currently have limited or no curative treatments available.
How similar studies have performed: Other studies utilizing multidisciplinary tumor boards have shown promise in improving treatment strategies, suggesting that this approach could be beneficial.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Participant must be considered likely incurable given the standard of care. This is inclusive of patients newly diagnosed, relapsed or in remission but at high risk of recurrence, with suboptimal responses to previous therapy, or with many potentially beneficial, but unlikely curative options for care. The site investigator will make this determination based on their experience. * Participant must have an age-appropriate performance status: Karnofsky 50 or more for patients 16 years of age or older OR Lansky score of 50 or more for patients less than16 years of age. * Participant and/or parents or legal guardian and primary oncologist must be willing to consider the therapeutic strategies recommended by the pedsETB. * Participant must be willing to be followed over time and allow collection of clinical data including scans, available blood and lab samples, and optional pedsETB serial blood sampling. * All Participants and/or their parents or legal guardians must have the ability to understand and the willingness to sign a written informed consent or assent document. Exclusion Criteria: * Participants without known therapies to reliably induce a response are excluded from pedsETB and should seek clinical trials.
Where this trial is running
Tampa, Florida
- Moffitt Cancer Center — Tampa, Florida, United States (Recruiting)
Study contacts
- Principal investigator: Jonathan Metts, MD — Moffitt Cancer Center
- Study coordinator: Jessica Crimella
- Email: Jessica.Crimella@moffitt.org
- Phone: 813-745-6250
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.